Markets Featured

How Much Is Doubling Pancreatic Cancer Survival Worth?

The FDA just approved daraxonrasib, the first drug to double survival in pancreatic cancer — and the first to crack the 'undruggable' RAS protein after forty years. Inside the science, the $46 billion company that refused to sell, and the race the approval just started.

Alpha One

27 Aug 2026 • 6 min read

This week the FDA approved a drug that oncologists have been calling impossible for forty years.

Daraxonrasib — brand name Rasonque, developed by Revolution Medicines of Redwood City, California — is now cleared for adults with metastatic pancreatic adenocarcinoma whose cancer has progressed after at least one prior treatment. In its 500-patient Phase 3 trial, patients on the drug lived twice as long as patients on standard chemotherapy. In pancreatic cancer, nothing has ever done that. When the data were presented at the American Society of Clinical Oncology meeting in June, the room gave a standing ovation — a reaction so rare in this field that it made news on its own.

The clinical story is remarkable. The business story underneath it may matter just as much for investors: the approval validates a technology platform that cracks what was long considered the single most important unsolved target in cancer biology, held by a company that has repeatedly refused to sell itself — and that Wall Street has repriced from $38 a share to over $215 in twelve months.

The Deadliest Major Cancer

Pancreatic cancer is where treatment progress goes to die. About 67,000 Americans are diagnosed each year, and only 13% survive five years, according to the American Cancer Society — the worst rate of any major cancer. The tumor metastasizes early, often before diagnosis. It sits deep in the abdomen, wrapped around critical blood vessels, so only about one in five patients is even eligible for surgery. And it builds a fibrous shell around itself that blocks both chemotherapy and the immune system.

For patients whose cancer has spread and progressed past first-line treatment, the standard of care has been more chemotherapy — harsh, toxic, and typically buying months. Many patients decline it entirely. Median survival in that second-line setting, per the control arm of the new trial: 6.6 months.

That is the baseline against which daraxonrasib doubled survival.

Briefings like this land in members' inboxes before the market prices them in. Join free →

Forty Years of "Undruggable"

The reason this approval resonates far beyond one disease is the target. More than 90% of pancreatic tumors are driven by mutations in a single gene: KRAS. The RAS gene family was identified in human cancer in the early 1980s — among the first cancer-driving genes ever found — and RAS mutations appear in roughly a quarter of all human cancers. It is, by a wide margin, the most common oncogene in the disease.

For four decades, nobody could hit it. Targeted cancer drugs work by burrowing into pockets on a protein's surface and jamming its function. The K-Ras protein has no such pockets — researchers nicknamed it the "greasy ball." Oncology conferences ran recurring sessions with titles like "Where are we with the undruggable K-Ras?" The answer, year after year, was nowhere.

The first crack came in 2021, when drugs emerged against one specific RAS mutation called G12C. But G12C is mostly a lung cancer mutation; it barely appears in pancreatic tumors, which are dominated by other variants. The hard problem — hitting RAS broadly, across mutations — stayed open.

Daraxonrasib solves it sideways. Instead of searching for a pocket that doesn't exist, the drug acts as a molecular clamp: it tethers RAS to another protein that naturally occurs inside the cell, physically blocking the active site. Because the mechanism doesn't depend on any one mutation's shape, it works across the mutant RAS variants that drive most pancreatic cancer — and potentially a long list of other tumors.

What the Data Showed

The Phase 3 trial, RASolute 302, published in the New England Journal of Medicine, randomized 500 previously treated metastatic pancreatic cancer patients to daraxonrasib or chemotherapy of the physician's choice:

Median overall survival: 13.2 months vs. 6.6 months — a hazard ratio of 0.40, meaning a 60% reduction in the risk of death
Median progression-free survival: 7.3 months vs. 3.5 months
Treatment discontinuation due to side effects: 1.2% on daraxonrasib vs. 11.2% on chemotherapy

That last number deserves attention. Daraxonrasib is an oral pill whose most common serious side effects are rash and mouth sores — unpleasant, but a different universe from the chemotherapy regimens pancreatic patients typically endure. Patients aren't just living twice as long; they're living those months on a tolerable daily pill instead of infusion chemotherapy. Oncologists interviewed about the drug consistently make the same point: this is not a cure, but it converts a rapid terminal illness into something patients can live with, for a while, with quality of life intact.

The FDA granted an expedited approval — the pivotal data were published in late May and the drug was approved before September. European regulators have the drug under accelerated review as well.

The $46 Billion Company That Wouldn't Sell

Revolution Medicines traded at $38 a year ago. It closed Wednesday at $215.44 — a market capitalization of roughly $46 billion, against essentially zero product revenue until now. That valuation is a bet on three things.

First, the approved indication itself. Second-line metastatic pancreatic cancer is a population with brutal turnover and, until this week, no targeted option at all — near-total penetration of eligible, tested patients is plausible in a way it rarely is in oncology.

Second, expansion. Daraxonrasib is already in Phase 3 for first-line metastatic pancreatic cancer and for RAS-mutant lung cancer, and a new trial is testing it after surgery to prevent recurrence — the setting where long-term survivorship, not months, is the prize. Each success multiplies the addressable population. Beyond daraxonrasib, the company's platform includes mutation-selective RAS inhibitors designed to be stacked with it as resistance emerges — because resistance will emerge; published work this month already maps the escape routes tumors use and the combinations meant to close them.

Third, scarcity. Revolution has conspicuously chosen to remain independent. In June 2025 it took $2 billion in flexible funding from Royalty Pharma — one of the largest financings ever for a pre-commercial biotech — precisely so it could launch the drug itself rather than sell the company or partner away economics. Takeover speculation has swirled all year (AbbVie publicly denied talks in January; Merck's name surfaces regularly), and every approval milestone makes an acquisition more expensive. In a pharma industry staring down patent cliffs later this decade, the first validated pan-RAS franchise is arguably the single most strategically valuable asset not yet owned by big pharma.

The risks are equally clear. The company's price now assumes flawless execution: a first-ever commercial launch, an unannounced price that will draw scrutiny, competitors racing into RAS from every direction, and the certainty that single-agent survival gains — however historic — eventually run into resistance. A $46 billion valuation leaves little room for stumbles. And the broader pan-RAS race is exactly that: a race, with multiple large-cap entrants now developing their own RAS programs, any of which could compress Revolution's window of exclusivity.

Why This Matters Beyond One Stock

Drug approvals happen every month. Platform validations happen a few times a decade. The reason this one belongs in the same conversation as the first checkpoint inhibitors or the first mRNA vaccines is what it proves: the largest, most common driver of human cancer is now druggable. Every tumor type with meaningful RAS mutation rates — colorectal, lung, and beyond — is now a live commercial question rather than a theoretical one.

For the pharma majors, the calculus just changed too. The "undruggable" label was, among other things, a reason not to spend. That reason is gone, and the resulting scramble — in-licensing, acquisitions, internal RAS programs — will shape oncology business development for years. Meanwhile the next wave is already visible: personalized mRNA vaccines for pancreatic cancer showed striking early durability in small trials and are moving through Phase 2. The deadliest major cancer has gone, in eighteen months, from a scientific dead end to one of the most competitive frontiers in medicine.

Patients got the better end of this week's news, and that is as it should be. But markets should take the point as well: forty-year problems are falling. The interesting question is always who owns the solution.

If this analysis was useful, this is what AlphaBriefing does every day — geopolitics and markets, connected to what it means for your money. Free members get the daily brief in their inbox; paid members get the investment frameworks, scenario pricing, and catalyst calendars behind the paywall.

Sign up free → — upgrade whenever it earns it.

Sources & Further Reading

Disclaimer

AlphaBriefing is an independent intelligence publication. The content in this article is produced for informational and educational purposes only. Nothing published by AlphaBriefing constitutes financial, investment, legal, tax, or regulatory advice, nor should it be construed as a solicitation or recommendation to buy, sell, or hold any security, asset, or financial instrument.

All views expressed are those of the author at the time of writing and are subject to change without notice. Markets are volatile and unpredictable; past performance is not indicative of future results. Any investment involves risk, including the possible loss of principal.

AlphaBriefing and its principals, employees, or contributors may hold positions in securities or assets mentioned in this article. This should be considered a potential conflict of interest. No material relationship with any company referenced exists unless explicitly disclosed. Readers should conduct their own due diligence and consult qualified financial, legal, and tax advisors before making any investment decisions.

Information in this article is drawn from public sources believed to be reliable at the time of publication. AlphaBriefing makes no warranty, express or implied, as to the accuracy, completeness, or timeliness of any information herein. AlphaBriefing accepts no liability for any loss or damage arising from reliance on this content.